SenesTech (SNES) AI Stock Analysis

• Market Cap: $14.05M
• Dividend Yield: N/A
• Average Volume (3M): 74.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: 39.37%
• EPS Growth: 69.81%
• Country: US
• Employees: 23
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): -0.28
• Shares Outstanding: 5,185,333
• 10 Day Avg. Volume: 64,952
• 30 Day Avg. Volume: 74,936
• PEG Ratio: <0.01
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 1.24
• P/FCF Ratio: -0.38
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 5.62
• Enterprise Value/Gross Profit: 8.85
• Enterprise Value/Ebitda: -2.28
• 1Y Price Target: $10.00
• Price Target Upside: 292.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -2.83
• Revenue Forecast (FY): $2.70M

• Rating: 49 Neutral
• Price Target: $3.00 ▲(17.65% Upside)

SenesTech's overall stock score is primarily impacted by its financial challenges, including negative profitability and cash flow issues. While the earnings call provided positive insights into revenue growth and improved metrics, the technical indicators and valuation remain weak, contributing to a lower overall score.

Positive Factors

Revenue Growth

The significant year-over-year revenue growth indicates strong market demand and successful product adoption, which can drive long-term business expansion and financial stability.

E-commerce Expansion

The robust growth in e-commerce sales highlights the company's effective online strategy, enhancing its market reach and supporting sustainable revenue streams.

Municipal Market Expansion

The expansion in municipal markets reflects increased adoption of the company's solutions, strengthening its position in urban pest management and supporting long-term growth.

Negative Factors

Profitability Challenges

Ongoing profitability issues, marked by negative margins, can hinder the company's ability to reinvest in growth and may affect its long-term financial health.

Cash Flow Concerns

Negative cash flows suggest operational inefficiencies and may limit the company's ability to fund future growth initiatives without external financing.

Decline in Core Product Revenue

The decline in revenue from ContraPest, the core product, raises concerns about product lifecycle and competitive pressures, potentially impacting long-term revenue stability.

SenesTech Business Overview & Revenue Model

Company Description

SenesTech, Inc. is a biotechnology company focused on developing innovative solutions for pest control through its proprietary technology. The company operates primarily in the agriculture and pest management sectors, providing environmentally friendly alternatives to traditional rodenticides. Its core product, ContraPest, targets rodent populations by disrupting their reproductive cycle, thus reducing their numbers without the use of harmful chemicals.

How the Company Makes Money

SenesTech generates revenue primarily through the sale of its flagship product, ContraPest, to various sectors including agriculture, municipalities, and commercial pest control operators. The company has established key partnerships with pest control companies and agricultural firms that help in distributing its product. Additionally, SenesTech may derive income from licensing agreements and potential collaborations with other biotech firms or research institutions aimed at expanding its product offerings and technology applications. The company's revenue model is centered around product sales, with a focus on building long-term relationships with clients to ensure repeat business.

SenesTech Financial Statement Overview

Summary

SenesTech is facing significant financial challenges, particularly in terms of profitability and cash flow. While there is some revenue growth, the company needs to address its operational inefficiencies to improve margins and cash flow. The balance sheet shows a moderate level of debt, but the negative return on equity highlights the need for strategic improvements to enhance shareholder value.

Income Statement

SenesTech has shown some revenue growth, with a 9.94% increase in the TTM period. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin is relatively healthy at 64.12%, but the consistent negative net income suggests ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.39, indicating a manageable level of debt relative to equity. However, the return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is not provided, but the overall leverage appears to be under control.

Cash Flow

SenesTech's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is somewhat aligned with net income, albeit both are negative. The company has not shown consistent improvement in free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.30M	1.86M	1.19M	1.02M	576.00K	258.00K
Gross Profit	1.46M	1.00M	539.00K	464.00K	220.00K	-23.00K
EBITDA	-5.67M	-6.01M	-7.57M	-9.51M	-7.95M	-7.62M
Net Income	-5.83M	-6.18M	-7.71M	-9.70M	-8.27M	-7.94M
Balance Sheet
Total Assets	14.62M	3.28M	7.29M	6.78M	11.50M	6.02M
Cash, Cash Equivalents and Short-Term Investments	10.25M	1.31M	5.39M	4.78M	9.33M	3.64M
Total Debt	2.68M	262.00K	406.00K	359.00K	555.00K	1.44M
Total Liabilities	3.28M	767.00K	942.00K	1.50M	1.47M	2.14M
Stockholders Equity	11.35M	2.51M	6.35M	5.28M	10.04M	3.88M
Cash Flow
Free Cash Flow	-5.44M	-6.12M	-7.71M	-8.75M	-7.88M	-7.22M
Operating Cash Flow	-5.30M	-6.03M	-7.57M	-8.58M	-7.78M	-7.11M
Investing Cash Flow	-3.10M	-56.00K	-149.00K	-170.00K	-99.00K	-67.00K
Financing Cash Flow	13.17M	2.00M	8.34M	4.20M	13.56M	8.88M

SenesTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNES, the sentiment is Negative. The current price of 2.55 is below the 20-day moving average (MA) of 2.89, below the 50-day MA of 3.50, and below the 200-day MA of 3.53, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 45.24 is Neutral, neither overbought nor oversold. The STOCH value of 65.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNES.

SenesTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
FSI	61 Neutral	$82.88M	44.91	5.08%	―	0.18%	-54.25%
SNES	49 Neutral	$14.05M	―	-77.79%	―	39.37%	69.81%
GURE	48 Neutral	$5.94M	-0.08	-43.37%	―	61.85%	49.02%
NTIC	44 Neutral	$69.78M	4,088.89	0.02%	1.35%	-0.97%	-99.67%
LOOP	41 Neutral	$75.91M	-6.45	―	―	11013.00%	39.85%

SenesTech Corporate Events

SenesTech Appoints Michael Edell as Interim COO

On November 7, 2025, SenesTech announced the appointment of Michael Edell as the Interim Chief Operating Officer, effective November 3, 2025. Under the terms of the employment agreement, Mr. Edell will receive a monthly salary of $30,000 and potential bonuses for Q4 2025 and Q1 2026, but will not be eligible for company-sponsored benefits. The agreement is for six months, with a 60-day notice period required for termination without cause.

The most recent analyst rating on (SNES) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.

SenesTech Reports Record Revenue Growth Amid Challenges

SenesTech’s recent earnings call painted a predominantly positive picture, highlighting record revenue growth and improved financial metrics. The company has seen substantial progress in e-commerce and municipal markets, despite facing challenges such as a decline in ContraPest revenue and high legal expenses. Overall, the sentiment was optimistic, with the positive aspects outweighing the negatives.

SenesTech Reports Record Revenue and Growth in Q3 2025

SenesTech, Inc., a leader in fertility control for managing animal pest populations, specializes in EPA-compliant Rodent Birth Control™ products, aiming to provide humane and sustainable pest management solutions.

SenesTech Appoints Michael Edell as Interim COO

On October 15, 2025, SenesTech appointed Michael Edell as Interim Chief Operating Officer. Mr. Edell, who has a background in founding and directing companies in the eco-friendly consumer goods and pet treat industries, will receive a monthly compensation of $30,000 and be eligible for bonuses, but will not receive standard benefits or severance due to the interim nature of the position.

The most recent analyst rating on (SNES) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.

SenesTech Registers Additional Shares for Market Offering

On September 24, 2025, SenesTech filed a prospectus supplement to register an additional $7,580,675 of shares of its common stock, as part of an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, initially dated June 20, 2024. Prior to this filing, the company had already sold $3,048,894.72 worth of shares under this agreement, indicating an ongoing strategy to raise capital through stock offerings.

The most recent analyst rating on (SNES) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.